CD38 and Miyoshi myopathy: Thus, this meta-analysis of phase III randomized controlled trials (RCTs) aimed to clarify the benefit of treatment with anti-CD38 monoclonal antibodies combined with proteasome inhibitors or immunomodulatory agents for patients with relapsed or refractory MM.